Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Abstract B007: Concordance between tumor tissue and plasma genotyping in NCI-MATCH Trial (EAY131)

Mohamed A Gouda, Filip Janku, Ying Yuan, Leylah Drusbosky, Alice P Chen, Keyur Patel, Stanley R Hamilton, Mark Routbort, P. Mickey Williams, John Iafrate, Jeffrey Sklar, Brent Coffey, Richard F Little, Carlos L Arteaga, Jeffrey S Abrams, Peter J O’Dwyer, Keith T Flaherty, Lyndsay N Harris, Funda Meric-Bernstam

Mol Cancer Ther (2023) 22 (12_Supplement): B007.

https://doi.org/10.1158/1535-7163.TARG-23-B007

Published: 01 December 2023

View articletitled, Abstract B007: Concordance between tumor tissue and plasma genotyping in NCI-MATCH Trial (EAY131)

Journal Articles

Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant Melanoma

McKenna Q. Glasheen, Signe Caksa, Amelia G. Young, Nicole A. Wilski, Connor A. Ott, Inna Chervoneva, Keith T. Flaherty, Meenhard Herlyn, Xiaowei Xu, Andrew E. Aplin, Claudia Capparelli

Mol Cancer Ther (2023) 22 (9): 1087–1099.

https://doi.org/10.1158/1535-7163.MCT-23-0025

Published: 05 September 2023

View articletitled, Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant Melanoma

Includes: Supplementary data

Journal Articles

The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission

Kenneth C. Anderson, Lewis C. Cantley, Riccardo Dalla-Favera, Chi Van Dang, Luis A. Diaz, Raymond N. DuBois, Keith T. Flaherty, Philip D. Greenberg, Massimo Loda, Elaine R. Mardis, Elizabeth A. Platz, Michael N. Pollak, Robert D. Schreiber, Lillian L. Siu, Beverly A. Teicher

Mol Cancer Ther (2022) 21 (11): 1625–1631.

https://doi.org/10.1158/1535-7163.MCT-22-0655

Published: 03 November 2022

View articletitled, The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission

Journal Articles

Abstract P117: Oncogenic Kit induces replication stress and induces Chk1/ATR inhibitor sensitivity in melanoma

Ching-Ni Njauw, Zhenyu Ji, Hensin Tsao, Antoine Simoneau, Raj Kumar, Keith T. Flaherty, Lee Zou, Duc Minh Pham

Mol Cancer Ther (2021) 20 (12_Supplement): P117.

https://doi.org/10.1158/1535-7163.TARG-21-P117

Published: 01 December 2021

View articletitled, Abstract P117: Oncogenic Kit induces replication stress and induces Chk1/ATR inhibitor sensitivity in melanoma

Journal Articles

Abstract LBA003: Erdafitinib in patients with tumors harboring FGFR gene mutations or fusions: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol K2

Mol Cancer Ther (2021) 20 (12_Supplement): LBA003.

https://doi.org/10.1158/1535-7163.TARG-21-LBA003

Published: 01 December 2021

View articletitled, Abstract LBA003: Erdafitinib in patients with tumors harboring FGFR gene mutations or fusions: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol K2

Journal Articles

A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer

Mol Cancer Ther (2020) 19 (2): 460–467.

https://doi.org/10.1158/1535-7163.MCT-19-0681

Published: 06 February 2020

View articletitled, A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer

Includes: Supplementary data

Journal Articles

Abstract A089: Adolescent and young adult (AYA) cohort of the NCI MATCH clinical trial (EAY131)

Alice P Chen, Shuli Li, Brent Coffey, James V Tricoli, Stanley R Hamilton, Mickey P Williams, Edith P Mitchell, David Patton, Robert J Gray, Lisa M McShane, Lawrence V Rubinstein, Carlos L Arteaga, Peter J O'Dwyer, Lyndsay N Harris, Barbara A Conley, Keith T Flaherty

Mol Cancer Ther (2019) 18 (12_Supplement): A089.

https://doi.org/10.1158/1535-7163.TARG-19-A089

Published: 01 December 2019

View articletitled, Abstract A089: Adolescent and young adult (AYA) cohort of the NCI MATCH clinical trial (EAY131)

Journal Articles

Abstract A079: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH): A successful precision medicine signal-seeking trial in patients (pts) with rare variants and refractory malignancies

Lyndsay N Harris, Robert J Gray, Barbara A Conley, Alice P Chen, Keith T Flaherty, Stanley R Hamilton, Paul M Williams, Chris Karlovich, David Patton, Shuli Li, Lisa M McShane, Larry V Rubinstein, Edith P Mitchell, James V Tricoli, Richard F Little, Carlos L Arteaga, Peter J O'Dwyer, NCI-MATCH team

Mol Cancer Ther (2019) 18 (12_Supplement): A079.

https://doi.org/10.1158/1535-7163.TARG-19-A079

Published: 01 December 2019

View articletitled, Abstract A079: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH): A successful precision medicine signal-seeking trial in patients (pts) with rare variants and refractory malignancies

Journal Articles

Abstract A053: Prevalence of mismatch repair deficiency (dMMR) in the NCI Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131) population

Barbara A. Conley, Stanley R. Hamilton, Shuli Li, Robert J. Gray, David R. Patton, Peter J. O'Dwyer, Robert L. Comis, Jeffrey S. Abrams, Nilofer S. Azad, Michael J. Overman, Jonathan D. Schoenfeld, Paul M. Williams, James V. Tricoli, Elad Sharon, Howard Streicher, Lyndsay N. Harris, Alice P. Chen, Keith T. Flaherty

Mol Cancer Ther (2018) 17 (1_Supplement): A053.

https://doi.org/10.1158/1535-7163.TARG-17-A053

Published: 01 January 2018

View articletitled, Abstract A053: Prevalence of mismatch repair deficiency (dMMR) in the NCI Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131) population

Journal Articles

Abstract PL03-01: NCI-MATCH: A new paradigm in the era of genomic oncology

Mol Cancer Ther (2018) 17 (1_Supplement): PL03-01.

https://doi.org/10.1158/1535-7163.TARG-17-PL03-01

Published: 01 January 2018

View articletitled, Abstract PL03-01: NCI-MATCH: A new paradigm in the era of genomic oncology

Journal Articles

Abstract LB-C05: Early exosome mRNA changes are associated with improved progression free survival of metastatic melanoma patents on ipilimumab: Identification of a novel exosome mRNA signature of ipilimumab response

Christine M. Coticchia, Ryan J. Sullivan, Keith T. Flaherty, James D. Hurley, Lan Hu, Shauna M. Blackmon, Graham Brock, Vincent T. O'Neill, Johan Skog

Mol Cancer Ther (2015) 14 (12_Supplement_2): LB-C05.

https://doi.org/10.1158/1535-7163.TARG-15-LB-C05

Published: 01 December 2015

View articletitled, Abstract LB-C05: Early exosome mRNA changes are associated with improved progression free survival of metastatic melanoma patents on ipilimumab: Identification of a novel exosome mRNA signature of ipilimumab response

Journal Articles

Abstract PR06: Phase 1b dose-escalation study of trametinib (MEKi) plus palbociclib (CDK4/6i) in patients with advanced solid tumors

Ryan J. Sullivan, Rodabe N. Amaria, Donald P. Lawrence, John Brennan, Cathie Leister, Rajendra Singh, Jeff Legos, Holger Thurm, Li Yan, Keith T. Flaherty, Michael A. Davies, Jeffrey Sosman

Mol Cancer Ther (2015) 14 (12_Supplement_2): PR06.

https://doi.org/10.1158/1535-7163.TARG-15-PR06

Published: 01 December 2015

View articletitled, Abstract PR06: Phase 1b dose-escalation study of trametinib (MEKi) plus palbociclib (CDK4/6i) in patients with advanced solid tumors

Journal Articles

Clinical Utility of a Blood-Based BRAF^V600E Mutation Assay in Melanoma

Mol Cancer Ther (2014) 13 (12): 3210–3218.

https://doi.org/10.1158/1535-7163.MCT-14-0349

Published: 04 December 2014

View articletitled, Clinical Utility of a Blood-Based BRAFV600E Mutation Assay in Melanoma

Includes: Supplementary data

Journal Articles

Abstract PR10: A cyclic AMP-regulated melanocyte lineage program confers resistance to MAP kinase pathway inhibition

Cory M. Johannessen, Laura A. Johnson, Federica Piccioni, Aisha Townes, Dennie T. Frederick, Keith T. Flaherty, Jennifer A. Wargo, David E. Root, Levi A. Garraway

Mol Cancer Ther (2013) 12 (5_Supplement): PR10.

https://doi.org/10.1158/1535-7163.PMS-PR10

Published: 01 May 2014

View articletitled, Abstract PR10: A cyclic AMP-regulated melanocyte lineage program confers resistance to MAP kinase pathway inhibition

Journal Articles

Abstract C137: Rapid assessment of TORC1 suppression as a functional biomarker predicting responsiveness to RAF and MEK inhibitors in BRAF-mutant melanoma patients.

Ryan B. Corcoran, S. Michael Rothenberg, Aaron N. Hata, Anthony C. Faber, Adriano Piris, Rosalynn M. Nazarian, Ronald D. Brown, Jason T. Godfrey, Daniel Winokur, John Walsh, Mari Mino-Kenudson, Shyamala Maheswaran, Jeffrey Settleman, Jennifer A. Wargo, Keith T. Flaherty, Daniel A. Haber, Jeffrey A. Engelman

Mol Cancer Ther (2013) 12 (11_Supplement): C137.

https://doi.org/10.1158/1535-7163.TARG-13-C137

Published: 01 November 2013

View articletitled, Abstract C137: Rapid assessment of TORC1 suppression as a functional biomarker predicting responsiveness to RAF and MEK inhibitors in BRAF-mutant melanoma patients.

Journal Articles

CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma

Roberto A. Salas Fragomeni, Hye Won Chung, Yosef Landesman, William Senapedis, Jean-Richard Saint-Martin, Hensin Tsao, Keith T. Flaherty, Sharon Shacham, Michael Kauffman, James C. Cusack

Mol Cancer Ther (2013) 12 (7): 1171–1179.

https://doi.org/10.1158/1535-7163.MCT-12-1171

Published: 07 July 2013

View articletitled, CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma

Includes: Supplementary data

Journal Articles

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas

Keiran S.M. Smalley, Mercedes Lioni, Maurizia Dalla Palma, Min Xiao, Brijal Desai, Suzanne Egyhazi, Johan Hansson, Hong Wu, Alastair J. King, Patricia Van Belle, David E. Elder, Keith T. Flaherty, Meenhard Herlyn, Katherine L. Nathanson

Mol Cancer Ther (2008) 7 (9): 2876–2883.

https://doi.org/10.1158/1535-7163.MCT-08-0431

Published: 11 September 2008

View articletitled, Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas

Includes: Supplementary data

Journal Articles

Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases

Keiran S.M. Smalley, Nikolas K. Haass, Patricia A. Brafford, Mercedes Lioni, Keith T. Flaherty, Meenhard Herlyn

Mol Cancer Ther (2006) 5 (5): 1136–1144.

https://doi.org/10.1158/1535-7163.MCT-06-0084

Published: 26 May 2006

View articletitled, Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases

Includes: Supplementary data

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract B007: Concordance between tumor tissue and plasma genotyping in NCI-MATCH Trial (EAY131)

Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant Melanoma

The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission

Abstract P117: Oncogenic Kit induces replication stress and induces Chk1/ATR inhibitor sensitivity in melanoma

Abstract LBA003: Erdafitinib in patients with tumors harboring FGFR gene mutations or fusions: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol K2

A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer

Abstract A089: Adolescent and young adult (AYA) cohort of the NCI MATCH clinical trial (EAY131)

Abstract A079: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH): A successful precision medicine signal-seeking trial in patients (pts) with rare variants and refractory malignancies

Abstract A053: Prevalence of mismatch repair deficiency (dMMR) in the NCI Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131) population

Abstract PL03-01: NCI-MATCH: A new paradigm in the era of genomic oncology

Abstract LB-C05: Early exosome mRNA changes are associated with improved progression free survival of metastatic melanoma patents on ipilimumab: Identification of a novel exosome mRNA signature of ipilimumab response

Abstract PR06: Phase 1b dose-escalation study of trametinib (MEKi) plus palbociclib (CDK4/6i) in patients with advanced solid tumors

Clinical Utility of a Blood-Based BRAF^V600E Mutation Assay in Melanoma

Abstract PR10: A cyclic AMP-regulated melanocyte lineage program confers resistance to MAP kinase pathway inhibition

Abstract C137: Rapid assessment of TORC1 suppression as a functional biomarker predicting responsiveness to RAF and MEK inhibitors in BRAF-mutant melanoma patients.

CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas

Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only